



Autumn

2019

this issue:

What is EQIPD?

EQIPD at the ECNP Congress

EQIPD at SFN 2019

EQIPD Quality System second phase

Help to disseminate

General Assembly October 2019

To the website

What is EQIPD?



The **European Quality In Preclinical Data** project ([EQIPD](#)) is a € 9.6-million IMI initiative to establish common guidelines to strengthen the robustness, rigor and validity of research data.

To explain in steps what is the project about, a series of short informational videos has been made. In case you have not watched them yet, find all videos here:

In case you have not watched them yet, find all videos here:

Video 1: [What is EQIPD?](#)

Video 2: [Why do we need EQIPD?](#)

Video 3: [The main objectives of EQIPD](#)

Video 4: [Implementing EQIPD in your lab](#)

Video 5: [EQIPD for researchers and students](#)

Video 6: [EQIPD and companies](#)

Video 7: [EQIPD is not only for researchers](#)

Video 8: [EQIPD focus on neuroscience](#)

Video 9: [The EQIPD consortium at a glance](#)

EQIPD at the ECNP Congress



A brainstorming session entitled '[Improving preclinical data quality in neuropsychopharmacological research: is the glass half empty or half full?](#)' took place at the last ECNP Congress (7-10 September 2019, Copenhagen, Denmark) to raise awareness amongst the international applied neuroscience community about preclinical data quality issues and the activities of the consortium.

The session presented the preclinical quality system and the certified training system for feedback from researchers in the field.

The project was also promoted with flyers and a large banner with the main information about EQIPD.

With around 5,500 participants, the ECNP Congress is Europe's premier showcase for new research, treatments and technologies in applied brain science.



EQIPD at SFN 2019

A poster about the project entitled '[The EQIPD framework for rigour in the design, conduct and analysis of biomedical experiments](#)' was presented at the last [SFN Meeting](#) on 19-23 October in Chicago, USA.

The project was also presented to conference delegates by [Noldus Information Technology](#), one of the EQIPD project members.

The SFN Meeting is the largest gathering of neuroscientists in the world and was attended by over 28,000 neuroscientists and other attendees.



EQIPD launches the second phase of beta-testing for its new quality system

The EQIPD Quality System (QS) is a flexible, fit-for-purpose, lean and user-friendly quality management system for non-regulated drug discovery research.

The EQIPD QS has been designed to support variable speeds of implementation, guided by the researchers' environment, financial situation and individual needs. To customise the implementation of the QS and to help scientists navigate information related to research quality, the EQIPD team has developed a specialised set of accompanying tools.

Pilot implementation of the QS in selected research laboratories in Europe commenced in May 2019, and following the initial feedback, various elements of the QS have been revised. In November 2019, EQIPD released an updated version of the tools and started a second phase of beta-testing in collaboration with the members of the stakeholder group.

A face-to-face meeting with the stakeholders will take place on 2-3 March 2020 in Frankfurt at the Goethe University campus.



Help to disseminate

As part of the project's dissemination drive, a poster featuring highlights of the EQIPD project has been created to explain the purpose of the project and its expected outcome.

Would you like to have a printed version of this poster to hang in your lab, university or company? Please let us now by [e-mail](#) and we will send the poster to you.



General Assembly last October

On 23-24 October, the EQIPD consortium got together for its annual General Assembly in Brussels. As well as reviewing progress on each of the eight work packages, the meeting discussed how the project's last 12 months should be used and prepared plans to ensure all of its ambitious goals are achieved.



Demonstrating the research vibrancy of the project, the EQIPD young scientists presented their current results by talks and posters:

- Maria Arroyo-Araujo (University of Groningen & Psychogenics INC) on how to harmonise data from different labs when testing a drug in mice using the open field test.
- Kaitlyn Hair (University of Edinburgh & Janssen Pharmaceutica NV) on how to use automation tools, such as machine learning and text mining approaches, to create a framework for the continual synthesis and quality assessment of clinical/animal and in vitro experiments studies of Alzheimer research.
- Ezgi Tanriver-Ayder (University of Edinburgh & Janssen Pharmaceutica NV) on historical data of open field test.
- Tim Ahuis (University of Groningen & Boehringer Ingelheim International GmbH) on cross-site validation EEG studies.
- Magdalena Smyk (University of Groningen & Janssen Pharmaceutica NV) on harmonization of baseline EEG in transgenic mouse model of tauopathy.
- Charmaine Lim (University of Aberdeen & Orion OYI) on the effects of EEG recording devices on the behavior of pharmacologically-induced mouse models of dementia?
- Jack Bray (University of Aberdeen) on Cross-site validation EEG studies.

In line with EQIPD's international scope, the US National Institutes of Health (NIH), the International Council for Laboratory Animal Sciences (ICLAS), Hindawi Ltd (Hindawi), BioCurate Pty Ltd (BioCurate) and Teva Pharmaceuticals LTD (Teva) were also represented at the meeting by respectively Shai Silberberg, Atsushi Iriki, Catriona J. MacCallum, C. Glenn Begley and Aric Orbach.

share on
Facebook & Twitter



Copyright © EQIPD 2019 Powered by ECNP

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777364. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

This newsletter reflects only the authors' views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.

Message in junk mail folder? Please add communication@ecnp.eu to your address book.
Don't want to receive our mail anymore? Please [click here](#). [Manage your subscriptions here](#)

If you can't read this e-mail [click here](#).